BeOne Medicines Ltd. ONC

Rank #2345 · Nasdaq · $535.2B market cap

Audited by Ernst & Young LLP, no going-concern flag in the latest filing.

Score

23.2

P/E

-607.0

P/B

122.10

ROE

-20.1%

Op. Margin

-49.1%

Debt Ratio

59%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★☆☆☆☆

Weak

P/E -607.0x, P/B 122.10x. Ranks in the top 80% of the universe.

Profitability ★☆☆☆☆

Poor

ROE -20.1%. Ranks in the top 84% of the universe.

Safety ★★★★☆

Good

Debt ratio 59%. Ranks in the top 26% of the universe.

Growth ★★★★★

Excellent

Revenue growth of 73.7% year over year. Ranks in the top 5% of the universe.

Growth is the relative strength · Valuation is the relative weakness (relative to this universe).

FY	Revenue	Op. Income	Net Income	Equity	Op. Margin%	Debt%
2016	$0.0B	$-0.0B	$-0.0B	$-0.1B	-120.9	-80
2017	$0.0B	$-0.1B	$-0.1B	$0.4B	-643.7	15
2018	$0.0B	$-0.1B	$-0.1B	$0.7B	-10940.2	54
2019	$0.2B	$-0.1B	$-0.1B	$1.7B	-41.3	29
2020	$0.2B	$-0.7B	$-0.7B	$1.0B	-356.1	66
2021	$0.4B	$-1.0B	$-0.9B	$3.9B	-224.2	45
2022	$0.3B	$-1.7B	$-1.6B	$6.1B	-536.7	39
2023	$1.2B	$-1.4B	$-1.5B	$4.4B	-122.3	46
2024	$1.4B	$-1.8B	$-2.0B	$6.1B	-126.4	37
2025	$2.5B	$-1.2B	$-0.9B	$4.4B	-49.1	59